Dose of Disruption: Will 2025 Healthcare Bounce Like the 2000s?

The Healthcare sector has been experiencing one of its most challenging performance periods on record, marked by significant underperformance relative to the broader market. This year, amid political pressures and tech’s AI-fueled dominance, the sector has lagged the S&P 500 by its widest margin in over two decades. Yet, with demographic tailwinds and innovative breakthroughs, is the healthcare sector overdue for a booster shot?

The chart below shows the healthcare sector’s price relative to the S&P 500 over the past 25 years, revealing that the sector hasn’t traded at such a deep discount since the early 2000s.

Source: Bloomberg, S&P 500 Healthcare Index relative to S&P 500

Current Headwinds: Politics, Costs, and Market Shifts

Healthcare’s recent checkup reveals a perfect storm of interconnected pressures. Intensified political scrutiny on U.S. drug prices, including efforts to align them with international levels and threats of up to 200% tariffs on pharmaceuticals, has heightened uncertainty for big pharma, biotech, and insurers. As of late 2025, with some tariff implementations underway, these risks have compounded cuts to Medicaid and health research funding, creating real obstacles for the sector.

Cost pressures add to the strain. Labour shortages persist, driving up expenses for providers, while post-pandemic inflation and rigid long-term contracts limit price adjustments. Efforts to pass costs to insurers or patients are met with resistance, squeezing profit margins. Broader market dynamics aren’t helping: expiring patents, underwhelming product launches, and operational hiccups at major insurers have tempered earnings outlooks. Meanwhile, investor capital has rotated toward booming tech, especially AI themes, leading to a 12-month outflow streak from healthcare ETFs.

Echoes of the Dot-Com Era

Today’s environment mirrors the healthcare sector’s struggles during the late 1990s dot-com bubble, when tech mania left defensive sectors in the dust. Back then, investors chased internet stocks, causing healthcare to underperform amid policy fears over rising costs and the potential insolvency of Medicare and Medicaid. Labor shortages in nursing roles and margin pressures from regulations further deterred interest.

Structural issues amplified the pain: hospitals grappled with input costs, and managed care faced volatility from pricing shifts and unprofitable markets. When the tech bubble burst in 2000-2002, healthcare endured the downturn and eventually attracted defensive flows. In the two years following the popping of the tech bubble in March 2000 through March 2002, the S&P Healthcare Index rose 29.91% while the broader S&P 500 stock index declined 15.86%.

For a clearer view, here’s how key aspects compare:

While these symptoms highlight recurring themes of rotation and uncertainty, but the prescription has evolved. Current woes tie more to tangible policies like enacted tariffs and inflation’s hangover, plus a highly concentrated S&P 500 where tech giants amplify relative underperformance.

Bright Spots Amid the Challenges

That said, healthcare’s structural growth potential shines brighter today. Aging populations in developed markets promise sustained demand for services and treatments. Innovations like obesity drugs (e.g., GLP-1 agonists) and AI applications in diagnostics and drug discovery offer real upside, even as near-term hurdles persist. Unlike the early 2000s, these tailwinds could accelerate recovery once policy fog clears. Think personalized medicine powered by data analytics, potentially transforming efficiency and outcomes.

Signs of Shifting Sentiment

Valuations may be reaching a tipping point. Take UnitedHealth Group, trading at its lowest price-to-earnings (P/E) multiple in years. This attracted Warren Buffett’s Berkshire Hathaway, making it the top hedge fund purchase of that week. Shares surged over 12% post-disclosure, adding nearly $50 billion in market cap, with gains persisting as investors interpret it as broader sector validation.

Looking Ahead

The slump stems from political uncertainty, cost squeezes, tech competition, and outflows. Echoes of the past amplified by today’s context. Yet, as valuations hit lows and some risks (like fading tariff threats) ease, sentiment could pivot. Improved earnings visibility and clarity on drug pricing or funding will be key. For those eyeing the long game, healthcare’s demographics and innovations underscore resilient fundamentals, rewarding patience in uncertain times.

The information contained in this article is for information purposes only, and represent the views of the author. It is not intended as specific investment or financial advice, or a recommendation or solicitation to buy or sell any security. Any investments or strategies listed in this article may not be suitable for all investors. Past performance is not indicative of future performance, and as with any investment, prices may fluctuate. It is recommended that advice is sought from a qualified investment professional prior to implementing any financial plan. LOM has made every effort to ensure that the contents herein have been compiled from sources believed reliable, however LOM does not warrant the accuracy, adequacy, timeliness, or completeness of this information expressly disclaims liability for errors or omissions in this information.